恒润达生：与华润双鹤就CD19CAR-T产品恒凯莱 达成商业化合作

Core Viewpoint - Shanghai Hengrun Da Biological Technology Co., Ltd. has announced a commercialization partnership with China Resources Double Crane Pharmaceutical Co., Ltd. for the Renikiorunase Injection (Hengkailai), granting exclusive national agency rights to China Resources Double Crane [1] Group 1: Company Overview - Hengrun Da is the first company in China to independently develop a CD19 CAR-T product targeting relapsed or refractory large B-cell lymphoma (r/r LBCL) [1] - China Resources Double Crane's acquisition of exclusive rights reflects its commitment to social responsibility and innovation in the biopharmaceutical sector [1] Group 2: Industry Implications - This collaboration represents a new exploration of collaborative development models in the field of tumor immunotherapy in China [1] - The partnership emphasizes the focus on clinical needs and the mission of innovation in therapeutic solutions within the biopharmaceutical industry [1]